A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer

Minamimoto, Ryogo; Toyohara, Jun; Ito, Hideyuki; Seike, Ayako; Miyata, Yoko; Morooka, Miyako; Okasaki, Momoko; Nakajima, Kazuhiko; Ito, Kimiteru; Ishiwata, Kiichi; Kubota, Kazuo

doi:10.1186/2191-219X-4-10

EJNMMI Research

Table 1 Clinical data and PET/CT findings in 31 patients with NSCLC

From: A pilot study of 4′-[methyl-¹¹C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer

Patient no.	Age	Sex	Pathology	Tumor diameter (mm)	TNM classification	Lymph node staging		SUVmax
								Primary lung lesion		Mediastinal positive uptake		Ascending aorta
						4DST	FDG	4DST	FDG	4DST	FDG	4DST	FDG
1	56	M	Adeno	31	pT2aN0M0	N0	N0	4.7	10.9	-	-	0.6	1.6
2	79	F	Adeno	14, 18	pT1aN0M0	N0	N0	1.8 to 2.1	1.3 to 2.8	-	-	1.1	2.2
3	55	F	Adeno	18	pT1aN0M0	N0	N0	4.1	7.7	-	-	1.0	1.7
4	60	M	Adeno	15	pT1aN2M0	N2	N0	1.5	1.4	1.7	-	0.7	1.7
5	69	M	Adeno	12	pT3N1M0	N2	N2	2.7	13.7	1.9 to 3.1	2.0 to 2.7	0.6	1.6
6	62	M	Adeno	32	pT2aN2M0	N2	N2	3.5	7.1	1.6 to 3.5	2.9 to 3.6	0.9	1.9
7	77	F	Adeno	20	pT1aN0M0	N0	N0	2.7	4.5	-	-	0.8	2.2
8	73	F	Adeno	15	pT2aN0M0	N3	N3	2.7	5.2	2.7 to 4.4	3.6 to 5.8	1.0	2.1
9	58	M	SCC	30	pT2aN1M0	N2	N0	3.0	5.6	2.1 to 2.5	-	0.8	1.7
10	55	M	Large cell	62	pT2bN1M0	N2	N2	3.2	7.6	1.9 to 2.0	1.7	1.0	1.8
11	72	M	Adeno	55	pT2bN0M0	N1	N0	4.5	10.1	3.0	-	0.9	2.3
12	74	M	SCC	30	pT2aN0M0	N1	N1	3.9	17.3	4.2	3.1	1.0	2.1
13	78	M	Adeno	38	pT2aN0M0	N0	N1	4.0	6.3	-	2.3	0.9	2.0
14	73	M	Adeno	20	pT1aN0M0	N2	N1	2.1	3.6	2.9 to 3.0	2.5 to 3.3	0.6	2.3
15	79	M	Adeno	19	pT1aN0M0	N2	N0	3.0	4.2	2.4 to 2.6	-	0.7	2.1
16	58	F	Adeno	18	pT1aN2M0	N2	N0	1.5	3.5	3.9 to 4.2	-	0.6	2.2
17	54	M	SCC	32	pT2aN0M0	N2	N0	1.6	0.8	2.2	-	0.7	1.6
18	84	M	Adeno	19	pT1aN0M0	N0	N0	1.9	1.2	-	-	0.5	2.1
19	76	M	Adeno	25	pT2aN0M0	N2	N0	6.5	13.5	3.0 to 5.3	-	0.6	1.8
20	75	M	Adeno	42	pT2aN2M0	N2	N0	5.2	3.6	1.7	-	0.7	2.0
21	70	M	SCC	45	pT3N1M0	N2	N0	5.6	15.7	2.8 to 2.9	-	0.4	1.7
22	73	M	Large cell	19	pT1aN0M0	N2	N0	2.8	4.2	1.7 to 2.4	-	0.6	1.8
23	76	M	Large cell	17	pT1aN2M0	N2	N2	1.7	2.8	2.1 to 3.1	4.1 to 4.4	0.4	1.5
24	88	M	SCC	70	pT3N0M0	N2	N2	5.1	18.8	4.7 to 5.6	2.7 to 3.6	0.4	1.9
25	36	F	Adeno	21	pT1bN0M0	N1	N1	4.4	3.3	2.9	2.7	0.7	2.0
26	76	F	SCC	60	pT2bN0M0	N2	N2	4.8	18.1	2.3 to 2.4	2.2 to 2.3	0.5	1.7
27	43	F	Adeno	28	pT2aN0M0	N1	N0	2.4	9.3	1.6	-	0.9	1.9
28	70	M	Adeno	20	T1bN2M1a	N2	N2	3.0	3.0	2.0 to 3.3	3.0	0.4	1.9
29	69	F	Adeno	22	T1aN0M1a	N3	N0	2.5	2.8	1.6, 1.6	-	0.6	1.7
30	70	M	Adeno	37	T2aN0M1a	N3	N0	4.7	12.2	2.6 to 4.9	-	0.7	2.3
31	61	F	Adeno	32	T2aN2M1a	N2	N2	3.3	8.9	1.7 to 4.1	3.1	0.5	1.6

NSCLC, non-small cell lung cancer; SUVmax, maximum standardized uptake value; M, male; F, female; Adeno, adenocarcinoma; SCC, squamous cell carcinoma; Large cell, large cell carcinoma.

Back to article page